

Susan Sm Webb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/982315/publications.pdf>

Version: 2024-02-01

228
papers

8,955
citations

44444

50
h-index

62345

84
g-index

238
all docs

238
docs citations

238
times ranked

5667
citing authors

#	ARTICLE	IF	CITATIONS
1	Complication Rates after Endoscopic Transsphenoidal Surgery for ACTH-Secreting Pituitary Adenomas: A Comparative Analysis with GH and Nonfunctioning Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, e274-e283.	0.4	1
2	Hypercortisolism and Behavioral Neuroscience. , 2022, , 293-298.		0
3	Hypopituitarism and pregnancy: clinical characteristics, management and pregnancy outcome. Pituitary, 2022, 25, 275-284.	1.6	5
4	Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience. Pituitary, 2022, 25, 420-432.	1.6	7
5	Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response. Biomedicines, 2022, 10, 460.	1.4	7
6	11-Deoxycorticosterone Producing Adrenal Hyperplasia as a Very Unusual Cause of Endocrine Hypertension: Case Report and Systematic Review of the Literature. Frontiers in Endocrinology, 2022, 13, 846865.	1.5	1
7	Consequences of Cushing's syndrome: Health versus personal costs. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	1
8	Data mining analyses for precision medicine in acromegaly: a proof of concept. Scientific Reports, 2022, 12, .	1.6	11
9	Quality of life impairment after a diagnosis of Cushing's syndrome. Pituitary, 2022, 25, 768-771.	1.6	10
10	Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain. Neuroendocrinology, 2021, 111, 925-936.	1.2	8
11	Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas. Clinical Endocrinology, 2021, 94, 811-819.	1.2	9
12	Quality of life in Cushing's syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101505.	2.2	16
13	Quality of life in pituitary tumors. , 2021, , 669-677.		0
14	EndoERN patient survey on their perception of health care experience and of unmet needs for rare endocrine diseases. Endocrine, 2021, 71, 569-577.	1.1	3
15	ESE audit on management of adult growth hormone deficiency in clinical practice. European Journal of Endocrinology, 2021, 184, 323-334.	1.9	14
16	Psychological complications of Cushing's syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 325-329.	1.2	5
17	Healthy snacks in hospitals: Testing the potential effects of changes in availability. Nutrition and Health, 2021, 27, 321-327.	0.6	2
18	Comprehensive Genetic Testing of CYP21A2: A Retrospective Analysis in Patients with Suspected Congenital Adrenal Hyperplasia. Journal of Clinical Medicine, 2021, 10, 1183.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2816-e2818.	1.8	0
20	Intramuscular fatty infiltration and physical function in controlled acromegaly. European Journal of Endocrinology, 2021, 185, 167-177.	1.9	7
21	Cross-species Association Between Telomere Length and Glucocorticoid Exposure. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5124-e5135.	1.8	6
22	Resistance to first-generation somatostatin receptor ligands does not impair the results of gamma knife radiosurgery in acromegaly. Clinical Endocrinology, 2021, 95, 849-855.	1.2	3
23	Prevalence of sarcopenia after remission of hypercortisolism and its impact on HRQoL. Clinical Endocrinology, 2021, 95, 735-743.	1.2	8
24	ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. European Journal of Endocrinology, 2021, 185, G1-G33.	1.9	39
25	Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas. European Journal of Endocrinology, 2021, 185, 485-496.	1.9	12
26	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology, 2021, 9, 847-875.	5.5	315
27	Immunotherapy-induced isolated ACTH deficiency in cancer therapy. Endocrine-Related Cancer, 2021, 28, 783-792.	1.6	8
28	Thigh Muscle Fat Infiltration Is Associated With Impaired Physical Performance Despite Remission in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2039-e2049.	1.8	17
29	Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes. Frontiers in Endocrinology, 2020, 11, 577173.	1.5	13
30	Patient-Centered Outcomes with Pituitary and Parasellar Disease. Neuroendocrinology, 2020, 110, 882-888.	1.2	9
31	Molecular profiling for acromegaly treatment: a validation study. Endocrine-Related Cancer, 2020, 27, 375-389.	1.6	39
32	Quality of Life in Patients With Cushing's Disease. Frontiers in Endocrinology, 2019, 10, 862.	1.5	28
33	Health-related quality of life improves 1 year after parathyroidectomy in primary hyperparathyroidism: A prospective cohort study. Clinical Endocrinology, 2019, 90, 184-191.	1.2	38
34	SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant. Journal of the Endocrine Society, 2019, 3, .	0.1	3
35	Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly. Endocrine Connections, 2019, 8, 39-49.	0.8	15
36	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	1.9	53

#	ARTICLE	IF	CITATIONS
37	Effects of Glucocorticoids on the Brain. , 2019, , 360-368.		0
38	MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission. Journal of the Endocrine Society, 2019, 3, .	0.1	0
39	MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI. Journal of the Endocrine Society, 2019, 3, .	0.1	0
40	Quality of life in patients with pituitary tumors. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 67-73.	0.6	1
41	Morbidity of Cushing's Syndrome and Impact of Treatment. Endocrinology and Metabolism Clinics of North America, 2018, 47, 299-311.	1.2	22
42	Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <sc>ERCUSYN</sc>. Clinical Endocrinology, 2018, 88, 787-798.	1.2	40
43	Quality of Life in Cushing's disease: A long term issue?. Annales D'Endocrinologie, 2018, 79, 132-137.	0.6	22
44	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37
45	Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. Journal of Medical Economics, 2018, 21, 382-389.	1.0	12
46	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology, the, 2018, 6, 17-26.	5.5	116
47	Patient-Centered Assessment on Disease Burden, Quality of Life, and Treatment Satisfaction Associated with Acromegaly. Journal of Investigative Medicine, 2018, 66, 653-660.	0.7	33
48	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology, 2018, 179, 97-108.	1.9	27
49	Clinical outcomes of childhood craniopharyngioma: can we do better?. Endocrine, 2018, 62, 1-2.	1.1	1
50	Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. European Journal of Endocrinology, 2018, 179, 419-427.	1.9	64
51	Cushing's disease: major difficulties in diagnosis and management during pregnancy. Minerva Endocrinology, 2018, 43, 435-445.	0.6	14
52	Aspectos novedosos en histopatología de la hipofisis. Endocrinología, Diabetes Y Nutrición, 2017, 64, 152-161.	0.1	9
53	BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Scientific Reports, 2017, 7, 42002.	1.6	27
54	Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management. Drugs, 2017, 77, 829-842.	4.9	102

#	ARTICLE	IF	CITATIONS
55	MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease. European Journal of Endocrinology, 2017, 177, R13-R26.	1.9	37
56	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
57	Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study. Clinical Endocrinology, 2017, 86, 806-815.	1.2	44
58	White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study. Pituitary, 2017, 20, 340-348.	1.6	25
59	Long-Term Effects of Prior Cushing's Syndrome. , 2017, , 199-224.		0
60	Development of ACRODAT [®] , a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 2017, 20, 692-701.	1.6	51
61	A polymorphism in the <i>CYP17A1</i> gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clinical Endocrinology, 2017, 87, 433-439.	1.2	19
62	Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. Clinical Endocrinology, 2017, 86, 214-222.	1.2	9
63	Update on quality of life in patients with acromegaly. Pituitary, 2017, 20, 185-188.	1.6	35
64	Cushing's syndrome and pregnancy outcomes: a systematic review of published cases. Endocrine, 2017, 55, 555-563.	1.1	87
65	Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing's Syndrome: Preliminary Study. BioMed Research International, 2017, 2017, 1-7.	0.9	19
66	Health-Related Quality of Life and Behavior in Patients with Both Pituitary and Hypothalamic Diseases. , 2017, , 343-354.		0
67	Patients' Perception On Clinical Outcome And Quality Of Life After A Diagnosis Of Cushing Syndrome. Endocrine Practice, 2016, 22, 51-67.	1.1	19
68	Cortisol Excess and the Brain. Frontiers of Hormone Research, 2016, 46, 74-86.	1.0	18
69	Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly. Endocrine, 2016, 53, 860-864.	1.1	10
70	El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la Endocrinología española por la medicina individualizada y la investigación traslacional. Endocrinología Y Nutrición: Organo De La Sociedad Española De Endocrinología Y Nutrición, 2016, 63, 274-284.	0.8	18
71	The Molecular Registry of Pituitary Adenomas (REMAH): A bet by Spanish Endocrinology for the future of individualized medicine and translational research. Endocrinología Y Nutrición (English Edition), 2016, 63, 274-284.	0.5	13
72	Reduced DNA methylation of FKBP5 in Cushing's syndrome. Endocrine, 2016, 54, 768-777.	1.1	37

#	ARTICLE	IF	CITATIONS
73	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. <i>Endocrine-Related Cancer</i> , 2016, 23, 871-881.	1.6	82
74	A specific nursing educational program in patients with Cushing's syndrome. <i>Endocrine</i> , 2016, 53, 199-209.	1.1	28
75	Brain metabolite abnormalities in ventromedial prefrontal cortex are related to duration of hypercortisolism and anxiety in patients with Cushing's syndrome. <i>Endocrine</i> , 2016, 53, 848-856.	1.1	20
76	Quality of Life in Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 106-111.	1.2	77
77	Validation of PHPQoL, a Disease-Specific Quality-of-Life Questionnaire for Patients With Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1571-1578.	1.8	27
78	Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. <i>Pituitary</i> , 2016, 19, 149-157.	1.6	30
79	Reduction of trabecular and cortical volumetric bone mineral density at the proximal femur in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 107-114.	1.9	15
80	Quality of life in patients with hypopituitarism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 306-312.	1.2	32
81	Dyslipidemia and Chronic Inflammation Markers Are Correlated with Telomere Length Shortening in Cushing's Syndrome. <i>PLoS ONE</i> , 2015, 10, e0120185.	1.1	39
82	Health-Related Quality of Life in Pituitary Diseases. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 161-170.	1.2	29
83	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. <i>European Journal of Endocrinology</i> , 2015, 173, R1-R14.	1.9	141
84	Quality of life in Cushing's syndrome. <i>Pituitary</i> , 2015, 18, 195-200.	1.6	30
85	Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E531-E541.	1.8	145
86	Relative adrenal insufficiency in severe acute variceal and non-variceal bleeding: influence on outcomes. <i>Liver International</i> , 2015, 35, 1964-1973.	1.9	12
87	The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL. <i>Pituitary</i> , 2015, 18, 876-883.	1.6	20
88	Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1242-E1254.	1.8	144
89	Impaired decision making and delayed memory are related with anxiety and depressive symptoms in acromegaly. <i>Endocrine</i> , 2015, 50, 756-763.	1.1	33
90	Pregnancy outcomes in women with growth hormone deficiency. <i>Fertility and Sterility</i> , 2015, 104, 1210-1217.e1.	0.5	38

#	ARTICLE	IF	CITATIONS
91	Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, 765-775.	1.9	35
92	Soluble TNF α -receptor 1 as a predictor of coronary calcifications in patients after long-term cure of Cushing's syndrome. <i>Pituitary</i> , 2015, 18, 135-141.	1.6	4
93	Adrenal Gland Hormones and the Vascular System. , 2015, , 4641-4651.		1
94	Acromegaly and the Vascular System. , 2015, , 4627-4633.		0
95	Benign and Malignant Nodular Thyroid Disease in Acromegaly. Is a Routine Thyroid Ultrasound Evaluation Advisable?. <i>PLoS ONE</i> , 2014, 9, e104174.	1.1	36
96	Genetic analysis does not confirm non-classical congenital adrenal hyperplasia in more than a third of the women followed with this diagnosis. <i>Hormones</i> , 2014, 13, 585-7.	0.9	1
97	Ten-Year Change in Quality of Life in Adults on Growth Hormone Replacement for Growth Hormone Deficiency: An Analysis of the Hypopituitary Control and Complications Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4581-4588.	1.8	36
98	Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. <i>Clinical Endocrinology</i> , 2014, 81, 883-890.	1.2	18
99	Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease. <i>European Journal of Endocrinology</i> , 2014, 171, 89-98.	1.9	26
100	Health-related quality of life in primary and secondary adrenal insufficiency. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 873-888.	0.7	24
101	Impaired decision-making and selective cortical frontal thinning in Cushing's syndrome. <i>Clinical Endocrinology</i> , 2014, 81, 826-833.	1.2	46
102	Telomere length analysis in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2014, 171, 21-29.	1.9	25
103	Prognosis of patients treated for Cushing syndrome. <i>Endocrinología Y Nutrición (English Edition)</i> , 2014, 61, 52-61.	0.5	9
104	Growth Hormone Should Be Used Only for Approved Indications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 409-411.	1.8	22
105	Biochemical and quality of life responses to octreotide-LAR in acromegaly. <i>Pituitary</i> , 2014, 17, 495-499.	1.6	28
106	Small cerebellar cortex volume in patients with active Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2014, 171, 461-469.	1.9	55
107	Pronóstico del paciente tratado de síndrome de Cushing. <i>Endocrinología Y Nutricion: Organó De La Sociedad Española De Endocrinología Y Nutricion</i> , 2014, 61, 52-61.	0.8	13
108	Development of a new tool for assessing Health-Related Quality of Life in patients with primary hyperparathyroidism. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 97.	1.0	33

#	ARTICLE	IF	CITATIONS
109	Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). <i>Pituitary</i> , 2013, 16, 115-121.	1.6	60
110	Mapping CushingQoL Scores onto SF-6D Utility Values in Patients with Cushing's Syndrome. <i>Patient</i> , 2013, 6, 103-111.	1.1	27
111	Endoscopic Surgery in the Skull Base Unit: Experience in the First 72 Cases. <i>Acta Otorrinolaringologica (English Edition)</i> , 2013, 64, 169-175.	0.1	0
112	Telomeres, aging and Cushing's syndrome: Are they related?. <i>Endocrinología Y Nutrición (English Edition)</i> 2013, 60, 136-143.	0.5	3
113	Psychometric Evaluation of the Cushing's Quality-of-Life Questionnaire. <i>Patient</i> , 2013, 6, 113-124.	1.1	36
114	Insuficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España. <i>Endocrinología Y Nutrición: Organó De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2013, 60, 136-143.	0.8	7
115	Adrenal insufficiency and adrenal replacement therapy. Current status in Spain. <i>Endocrinología Y Nutrición (English Edition)</i> , 2013, 60, 136-143.	0.5	3
116	How good is perceived health-related quality of life in patients treated for non-functioning pituitary adenomas?. <i>Clinical Endocrinology</i> , 2013, 78, 21-22.	1.2	2
117	Coronary Artery Disease Detected by Multislice Computed Tomography in Patients After Long-Term Cure of Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1093-1099.	1.8	44
118	Telomeres and endocrine dysfunction of the adrenal and GH/IGF-1 axes. <i>Clinical Endocrinology</i> , 2013, 79, 751-759.	1.2	22
119	Hippocampal dysfunction in cured Cushing's syndrome patients, detected by ¹ H-MR spectroscopy. <i>Clinical Endocrinology</i> , 2013, 79, 700-707.	1.2	34
120	Adrenal Gland Hormones and the Vascular System. , 2013, , 1-13.		0
121	A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome. <i>Clinical Endocrinology</i> , 2012, 77, 735-742.	1.2	83
122	Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice. <i>European Journal of Endocrinology</i> , 2012, 167, 337-342.	1.9	50
123	Immediate and delayed postoperative morbidity in functional and non-functioning pituitary adenomas. <i>Pituitary</i> , 2012, 15, 380-385.	1.6	10
124	Clinical consequences of Cushing's syndrome. <i>Pituitary</i> , 2012, 15, 319-329.	1.6	50
125	The value of a European registry for pituitary adenomas: The example of Cushing's syndrome registry. <i>Annales D'Endocrinologie</i> , 2012, 73, 83-89.	0.6	6
126	Verbal and Visual Memory Performance and Hippocampal Volumes, Measured by 3-Tesla Magnetic Resonance Imaging, in Patients with Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 663-671.	1.8	142

#	ARTICLE	IF	CITATIONS
127	Cost of Clinical Management of Acromegaly in Spain. <i>Clinical Drug Investigation</i> , 2012, 32, 235-245.	1.1	25
128	Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1589-1597.	1.8	229
129	Neuroendocrinology in 2011. <i>Endocrinología Y Nutrición (English Edition)</i> , 2012, 59, 311-325.	0.5	2
130	The OASIS study: Therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies. <i>Endocrinología Y Nutrición (English Edition)</i> , 2011, 58, 478-486.	0.5	9
131	Coping with 'cured' pituitary tumors. <i>Nature Reviews Endocrinology</i> , 2011, 7, 251-252.	4.3	13
132	Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10. <i>European Journal of Endocrinology</i> , 2011, 164, 355-362.	1.9	27
133	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. <i>European Journal of Endocrinology</i> , 2011, 165, 383-392.	1.9	322
134	Identification of Novel GH-regulated Genes in C2C12 Cells. <i>Hormone and Metabolic Research</i> , 2011, 43, 919-930.	0.7	5
135	Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4973-4978.	1.8	94
136	Body Composition After Endogenous (Cushing's Syndrome) and Exogenous (Rheumatoid Arthritis) Exposure to Glucocorticoids. <i>Hormone and Metabolic Research</i> , 2010, 42, 613-618.	0.7	21
137	Metabolic, Cardiovascular, and Cerebrovascular Outcomes in Growth Hormone-Deficient Subjects with Previous Cushing's Disease or Non-Functioning Pituitary Adenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 630-638.	1.8	63
138	Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain. <i>Endocrinología Y Nutrición: Organó De La Sociedad Española De Endocrinología Y Nutrición</i> , 2010, 57, 39-42.	0.8	9
139	Short- and long-term changes of quality of life in patients with acromegaly: Results from a prospective study. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 20-25.	1.8	33
140	Improving Quality of Life in Patients with Pituitary Tumours. <i>European Endocrinology</i> , 2010, 9, 32.	0.8	7
141	Changing Patterns of the Adult Growth Hormone Deficiency Diagnosis Documented in a Decade-Long Global Surveillance Database. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 392-399.	1.8	54
142	Persistent Body Fat Mass and Inflammatory Marker Increases after Long-Term Cure of Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3365-3371.	1.8	137
143	A Link between Bone Mineral Density and Serum Adiponectin and Visfatin Levels in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3889-3896.	1.8	52
144	Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2634-2643.	1.8	125

#	ARTICLE	IF	CITATIONS
145	Relationship Between Adiponectin and Left Atrium Size in Uncomplicated Obese Patients: Adiponectin, a Link Between Fat and Heart. <i>Obesity Surgery</i> , 2009, 19, 1324-1332.	1.1	42
146	Deleterious Effects of Glucocorticoid Replacement on Bone in Women After Long-Term Remission of Cushing's Syndrome. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1841-1846.	3.1	51
147	Quality of life in patients with pituitary tumors. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 299-303.	1.2	34
148	Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. <i>European Journal of Endocrinology</i> , 2008, 158, 623-630.	1.9	193
149	Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. <i>European Journal of Endocrinology</i> , 2008, 159, 773-779.	1.9	21
150	Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3853-3859.	1.8	153
151	Rab18 Is Reduced in Pituitary Tumors Causing Acromegaly and Its Overexpression Reverts Growth Hormone Hypersecretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2269-2276.	1.8	25
152	Long-lasting Subclinical Addison's Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 530-532.	0.6	16
153	Voltage-dependent Na ⁺ channel phenotype changes in myoblasts. Consequences for cardiac repair†. <i>Cardiovascular Research</i> , 2007, 76, 430-441.	1.8	11
154	Quality of Life in Growth Hormone Deficiency and Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 221-232.	1.2	26
155	Splanchnic and Hepatic Metabolism of Somatostatin: A Study in Cirrhotic Patients with a Portacaval Shunt. <i>Hepatology</i> , 2007, 3, 193-197.	3.6	12
156	Treatment of acromegaly improves quality of life, measured by AcroQoL. <i>Clinical Endocrinology</i> , 2007, 67, 358-362.	1.2	60
157	Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. <i>European Journal of Endocrinology</i> , 2006, 155, 269-277.	1.9	166
158	Quality of Life in Acromegaly. <i>Neuroendocrinology</i> , 2006, 83, 224-229.	1.2	61
159	Chrelin Is Produced by and Directly Activates Corticotrope Cells from Adrenocorticotropin-Secreting Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2225-2231.	1.8	44
160	Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). <i>Clinical Endocrinology</i> , 2005, 63, 103-110.	1.2	75
161	Quality of Life (QOL) in Patients with Acromegaly Is Severely Impaired: Use of a Novel Measure of QOL: Acromegaly Quality of Life Questionnaire. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3337-3341.	1.8	177
162	Determinants of neurosurgical outcome in pituitary tumors. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 787-794.	1.8	13

#	ARTICLE	IF	CITATIONS
163	Long-Term Improvement of Quality of Life During Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency, as Measured by Questions on Life Satisfaction-Hypopituitarism (QLS-H). Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1684-1693.	1.8	116
164	Growth Hormone (GH) Insensitivity Syndrome due to a GH Receptor Truncated after Box1, Resulting in Isolated Failure of STAT 5 Signal Transduction. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1259-1266.	1.8	65
165	Testosterone replacement therapy: current trends and future directions. Human Reproduction Update, 2004, 10, 409-419.	5.2	191
166	Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology, 2004, 151, 439-446.	1.9	334
167	Acromegaly Quality of Life Questionnaire (AcroQoL). Health and Quality of Life Outcomes, 2004, 2, 13.	1.0	102
168	Pancreatic vasoactive intestinal peptide-producing tumor and hypercalcemia. European Journal of Internal Medicine, 2004, 15, 328.	1.0	0
169	Neuromuscular dysfunction in adult growth hormone deficiency. Clinical Endocrinology, 2003, 59, 450-458.	1.2	12
170	Long-Term GH Therapy: Epidemiology and Auxologic Outcome. Hormone Research in Paediatrics, 2002, 57, 113-119.	0.8	4
171	Human Growth Hormone Replacement in Adult Hypopituitary Patients: Long-Term Effects on Body Composition and Lipid Status—3-Year Results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1600-1606.	1.8	109
172	Twenty-two years' survival of metastatic gastrinoma evidenced recently by somatostatin-receptor-specific scintigraphy. European Journal of Gastroenterology and Hepatology, 2002, 14, 333-336.	0.8	2
173	Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clinical Endocrinology, 2002, 57, 251-258.	1.2	151
174	Oncological complications of excess GH in acromegaly. Pituitary, 2002, 5, 21-25.	1.6	53
175	Human Growth Hormone Replacement in Adult Hypopituitary Patients: Long-Term Effects on Body Composition and Lipid Status—3-Year Results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1600-1606.	1.8	88
176	Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient. Pituitary, 2001, 4, 275-278.	1.6	4
177	Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clinical Endocrinology, 2000, 53, 577-586.	1.2	95
178	Antiproliferative Effect and Cell Cycle Modulation by Melatonin on GH ₃ Cells. Hormone Research in Paediatrics, 2000, 53, 251-255.	0.8	35
179	Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA) Tj ETQq1 1 0.784314 rgBT /Over	1.9	63
180	Recovery of Hypopituitarism after Neurosurgical Treatment of Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3696-3700.	1.8	189

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness and accuracy of the tests used in the differential diagnosis of Cushing's syndrome. Pituitary, 1999, 1, 125-132.	1.6	6
182	Biochemical liver abnormalities in Turner's syndrome. European Journal of Gastroenterology and Hepatology, 1999, 11, 1037-1040.	0.8	37
183	Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Clinical Endocrinology, 1998, 49, 53-61.	1.2	94
184	Fibromyalgia and melatonin: are they related?. Clinical Endocrinology, 1998, 49, 161-162.	1.2	12
185	Reversible endocrine dysfunction and pituitary stalk enlargement. Journal of Endocrinological Investigation, 1998, 21, 122-127.	1.8	9
186	Hyponatraemia in a prepubertal middle-aged woman.. Postgraduate Medical Journal, 1998, 74, 315-316.	0.9	0
187	Somatostatin and Somatostatin Receptor Subtype Gene Expression in Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2417-2420.	1.8	52
188	Management of Cervical Intraepithelial Neoplasia during Pregnancy with LOOP Excision. Gynecologic Oncology, 1997, 64, 153-155.	0.6	159
189	Myocardial damage does not occur in untreated hyperthyroidism unless associated with congestive heart failure. American Heart Journal, 1997, 134, 1133-1137.	1.2	16
190	Circannual Somatostatin Gene and Somatostatin Receptor Gene Expression in the Early Post-Natal Rat Pineal Gland. Neuroendocrinology, 1997, 66, 368-374.	1.2	9
191	The safety profile of GH replacement therapy in adults. Clinical Endocrinology, 1997, 46, 473-481.	1.2	70
192	Cushing's disease and pregnancy: Report of six cases. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1996, 64, 143-146.	0.5	52
193	Bronchial carcinoid tumor presenting as a thyroid nodule: An unusual clinical manifestation. Journal of Endocrinological Investigation, 1996, 19, 186-189.	1.8	1
194	Expression of the somatostatin gene and receptors in the rat Harderian gland. , 1996, 34, 118-122.		5
195	Thirty years of human pineal research: Do we know its clinical relevance?. Journal of Pineal Research, 1996, 20, 1-6.	3.4	12
196	Role of melatonin in health and disease. Clinical Endocrinology, 1995, 42, 221-234.	1.2	109
197	A gonadotrophin dependent stromal luteoma: a rare cause of postmenopausal virilization. Clinical Endocrinology, 1995, 43, 645-649.	1.2	21
198	In vivo and in vitro Flow Cytometry Comparative Analysis of Somatostatin-Positive Cells in the Pineal Gland of the Neonatal Rat. Neuroendocrinology, 1995, 62, 87-92.	1.2	3

#	ARTICLE	IF	CITATIONS
199	Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics. <i>Fertility and Sterility</i> , 1994, 62, 926-931.	0.5	7
200	Expression of somatostatin in rat pineal cells in culture. <i>Journal of Pineal Research</i> , 1993, 15, 43-45.	3.4	15
201	Dopaminergic resistance in a case of invasive macroprolactinoma. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 443-447.	1.8	8
202	Melatonin-Related Hypogonadotropic Hypogonadism. <i>New England Journal of Medicine</i> , 1992, 327, 1356-1359.	13.9	72
203	Computerized tomography versus magnetic resonance imaging: a comparative study in hypothalamicâ€pituitary and parasellar pathology. <i>Clinical Endocrinology</i> , 1992, 36, 459-465.	1.2	36
204	Harderian Gland Peptides. , 1992, , 235-243.		6
205	Circulating Hypersomatostatinaemia in Menetrier's Disease. <i>Hormone and Metabolic Research</i> , 1991, 23, 146-147.	0.7	0
206	Regional Distribution of Immunoreactive Somatostatin in the Bovine Pineal Gland. <i>Neuroendocrinology</i> , 1989, 50, 550-554.	1.2	13
207	Enhanced circadian rhythm of melatonin in anorexia nervosa. <i>European Journal of Endocrinology</i> , 1989, 120, 574-578.	1.9	39
208	Gastrin and Somatostatin Levels in Patients with Gastric Cancer. <i>Hormone and Metabolic Research</i> , 1989, 21, 89-91.	0.7	2
209	Stimulatory effect of prolactin on the mitotic activity of the adrenal cortex in snell mice with hereditary dwarfism. <i>Research in Experimental Medicine</i> , 1988, 188, 87-94.	0.7	5
210	Rhythms in Pineal Immunoreactive Somatostatin in the Syrian Hamster, Mouse, and Gerbil. <i>Journal of Pineal Research</i> , 1988, 5, 273-278.	3.4	11
211	Identification of immunoreactive somatostatin in the rat Harderian gland: Regulation of its content by growth hormone, beta-adrenergic agonists and calcium channel blockers. <i>Peptides</i> , 1988, 9, 571-574.	1.2	8
212	Plasma Immunoreactive Somatostatin is Elevated in Diabetic Ketoacidosis and Correlates with Plasma Nonâ€sterified Fatty Acid Concentration. <i>Diabetic Medicine</i> , 1987, 4, 221-224.	1.2	7
213	Circulating Immunoreactive Somatostatin in Gastrointestinal Diseases: Decrease after Vagotomy and Enhancement in Active Ulcerative Colitis, Irritable Bowel Syndrome, and Duodenal Ulcer. <i>Scandinavian Journal of Gastroenterology</i> , 1987, 22, 931-937.	0.6	24
214	ENDOCRINE ASPECTS OF PITUITARY STALK ENLARGMENT. <i>Clinical Endocrinology</i> , 1987, 27, 25-32.	1.2	15
215	Cysteamine effects on somatostatin, catecholamines, pineal NAT and melatonin in rats. <i>Brain Research Bulletin</i> , 1986, 16, 315-320.	1.4	7
216	Influence of Î³-sleep inducing peptide on melatonin synthesis in the rat pineal gland. <i>Neuroscience Letters</i> , 1986, 70, 127-131.	1.0	3

#	ARTICLE	IF	CITATIONS
217	ACTH and prolactin deficiency. European Journal of Endocrinology, 1986, 111, 296-299.	1.9	4
218	Hormonal modulation of pineal melatonin synthesis in rats and syrian hamsters: Effects of adrenalectomy and corticosteroid implants. Journal of Neural Transmission, 1985, 64, 67-79.	1.4	19
219	Effect of Long and Short Photoperiod and/or Pinealectomy on Immunoreactive Somatostatin in the Syrian Hamster. Hormone and Metabolic Research, 1985, 17, 107-108.	0.7	3
220	Photoreceptor Damage and Eye Pigmentation: Influence on the Sensitivity of Rat Pineal N-Acetyltransferase Activity and Melatonin Levels to Light at Night. Neuroendocrinology, 1985, 40, 205-209.	1.2	51
221	Circulating immunoreactive somatostatin in man. Effect of age, pregnancy, growth hormone deficiency and achlorhydria. European Journal of Endocrinology, 1985, 110, 145-151.	1.9	14
222	Autonomic regulation of postprandial plasma somatostatin, gastrin, and insulin.. Gut, 1985, 26, 683-688.	6.1	24
223	Hormonal Modulation of Cyclic Melatonin Production in the Pineal Gland of Rats and Syrian Hamsters: Effects of Thyroidectomy or Thyroxine Implant. Chronobiology International, 1985, 2, 177-183.	0.9	16
224	Deficiency of immunoreactive somatostatin in the median eminence of snell dwarf mice. Life Sciences, 1985, 36, 1239-1245.	2.0	7
225	STUDIES ON THE MECHANISMS OF SOMATOSTATIN RELEASE AFTER INSULIN INDUCED HYPOGLYCAEMIA IN MAN. Clinical Endocrinology, 1984, 21, 667-675.	1.2	12
226	Possible mechanisms of TSH independent thyroid growth. Medical Hypotheses, 1984, 14, 141-160.	0.8	8
227	IMMUNOREACTIVE SOMATOSTATIN IN THE PINEAL GLAND OF DIFFERENT RODENT SPECIES: CIRCADIAN RHYTHM, EFFECTS OF SUPERIOR CERVICAL GANGLIONECTOMY, PINEAL INDOLE ADMINISTRATION AND LIGHTING CONDITIONS. Biomedical Research, 1984, 5, 473-480.	0.3	12
228	Liver disease in brucellosis. A clinical and pathological study of 40 cases. Postgraduate Medical Journal, 1982, 58, 346-350.	0.9	90